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INTRODUCTION
Respiratory syncytial virus (RSV), an enveloped RNA virus of the paramyxovirus family, is the major cause of severe lower respiratory tract infection in infants and young children (Kim et al., 1973) . Attempts at vaccination with both killed and live attenuated vaccines have been unsuccessful and a useful RSV vaccine is currently not available (Kim et aL, 1969; Belshe et al., 1982) . Recent efforts have been directed at characterization of those RSV proteins which induce biologically important antibodies, with the hope that this information will be useful in the development of a successful vaccine.
Similar to other paramyxoviruses, RSV has two envelope glycoproteins which mediate infectivity and spread of virus. A 90000 tool. wt. (90K) glycoprotein, GP90, probably initiates infection via attachment of the virus to the host cell (Walsh et al., 1984a) . A 70K glycoprotein, VP70, is the RSV fusion protein (Walsh & Hruska, 1983) . The fusion protein, composed of disulphide-linked fragments of 48K and 23K, probably mediates virus entry into cells by fusion of viral and cellular membranes . The fusion protein induces syncytium formation in tissue culture by fusing the membranes of infected cells to adjacent uninfected cells, thereby promoting cell-cell spread of virus. Similar to other paramyxoviruses (Merz et al., 1981) , antibody to the attachment protein (GP90), although capable of neutralizing virus, is unable to halt cell-cell spread of virus since syncytium formation is not inhibited (Walsh et al,, 1984a) . Antibody to the fusion protein, on the other hand, neutralizes virus and inhibits syncytium formation, thereby effectively preventing cell-cell spread of virus (Walsh & Hruska, 1983; Walsh et al., 1985) . However, monoclonal and monospecific polyclonal antibodies to the fusion protein which neutralize virus but do not inhibit syncytium formation have been described Walsh et al., 1985) , thus suggesting that antibody must bind to a specific epitope on the fusion protein in order to inhibit its function.
In this report, we describe the topographical map of the RSV fusion protein including fusioninhibiting and neutralizing epitopes, utilizing both monoclonal and polyclonal antibodies. The results are discussed with regard to vaccine development and the evaluation of RSV strain differences.
METHODS

Virus and cells.
HEp-2 cells were rnaintained in MEM supplemented with 2 mM-glutamine and 5~ foetal calf serum. The Long strain of RSV was used for all experiments and had a titre of 2 x 10 ~' p.f.u./ml.
Monoclonal antibodies (MAbs) . Thirteen MAbs to VP70 were used. Seven of these (L4, R661, R392, R13-1, R136, 332-4, R294) have been previously described while six others have not (Taylor et al., 1984 Walsh & Hruska, 1983) . R235 was produced by immunizing a mouse with a BALB/c cell line persistently infected with RSV as described by . Five additional MAbs were produced by immunizing a BALB/c mouse with 4 vtg of purified VP70 in complete Freund's adjuvant (Walsh et al., 1985) . Four weeks later 4 pg of VP70 in incomplete Freund's adjuvant was given followed by a second boost of 2 gg of VP70 at 6 weeks. The spleen cells were fused with P3-X63-Ag8.653 cells according to published methods (Fazekas de St. Groth & Scheidegger, 1980) . After screening by indirect immunofluorescence, secreting hybridomas were subcloned by limiting dilution. Mouse ascitic fluid containing the MAbs was used in all experiments. The total protein content of each ascitic fluid was determined by Coomassie Brilliant Blue assay (Sigma) and electrophoresis on cellulose acetate membranes was performed. The preparations were then scanned and the areas under the curves integrated by densitometry. The MAb peaks were identified and protein concentrations of these were calculated as a percentage of the total protein. The concentration of MAb ranged from 4.5 to 24.6 mg/ml.
Potyctonal rabbit antisera to VP70. Two previously described :.monospecific rabbit antisera to different preparations of purified VP70 were used (Walsh et al., 1985) . One of these (14-07) neutralized virus and inhibited fusion, while the other (14-06) neutralized virus but did not inhibit fusion.
SoIM-phase immunoassay. The binding characteristics and the competitive interaction among the monoclonal and polyclonal antibodies were performed by a solid-phase enzyme-linked immunoassay. Fifty ng of purified fusion protein in 100 gl of coating buffer (0.1 M-NaH_,CO 3 pH 9.9) was adsorbed (4 ~C, 18 h) onto polystyrene plates (Dynatech Immulon-2). The wells were emptied and blocked with 1 ° o bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 h at room temperature. For the binding assay, 100/al of various dilutions of ascitic fluids in 1 °/o BSA PBS containing 0.1 ~ Tween-20 (PBS-BSA-Tw) was incubated in antigen-coated wells in duplicate for 2 h at 37 °C. After washing with PBS BSA Tw, alkaline phosphatase-labelled rabbit anti-mouse IgG was added for 1 h at 37 °C, followed by 200 ~tl of substrate for 30 min. The ahsorbance at 410 nm was recorded with a Dynatech MR600 Microelisa reader. Competition among the monoclonal and polyclonal antibodies was performed by simultaneously incubating alkaline phosphatase-labelled MAb with dilutions of unlabelled competitor antibody. All polyclonal and monoclonal antibodies were conjugated to alkaline phosphatase according to the method of Voller et al. (1976) .
Neutralization and inhibition aJ[usion assays. Neutralizing ability was determined by a 50~ / plaque reduction assay; all antibodies with a titre greater than 1 : 100 in the absence of complement were considered neutralizing. The ability of an antibody to inhibit fusion of previously infected cells was performed as previously described (Walsh & Hruska, 1983) . Briefly, monolayers of 2 x 105 HEp-2 cells were infected with RSV at an m.o.i, of 0.01. Eight h later the medium was removed and the monolayer covered with 1 ml MEM containing the MAb. After 2 days, cell-cell spread of virus was assayed by direct immunofluorescence using a MAb to the nucleocapsid protein.
All antibodies were screened initially at 1 : 100 dilutions, and fusion-inhibiting antibodies were titrated to the highest dilation that gave complete absence of syncytia after 4 days as determined by light microscopy.
PAGE and Western blotting. Five gg of purified VP70 in 500 gl of sample buffer with or without 2-mercaptoethanol (2-ME) was electrophoresed on a 12°,'o SDS polyacrylamide gel as previously described (Walsh et al., 1985) . The sample was either boiled for 3 min or kept at room temperature prior to electrophoresis. Previous work demonstrated that VP70 migrates as a dimer when electrophoresed without prior heat treatment, as a monomer when heated without 2-ME reduction, and as 48K and 23K fragments when treated with 2-ME and heat (Walsh et al., 1985) . Following SDS-PAGE, the proteins were transferred to nitrocellulose paper which was cut into strips and incubated for 1 h with 2 ml of buffer (0-05 M-Tris HC1, 0-9 M-NaC1 pH 7-4, 0.1 ~ Tween) containing 10 ~tg of MAb. After washing in buffer, the strips were incubated in 2 ml of a 1:200 dilution of rabbit anti-mouse IgG antibody (Cappel Laboratories) followed by 200000 c.p.m. ~ 25I-labelled staphylococcal Protein A (IPA, New England Nuclear). The strips were autoradiographed using a Cronex intensifier screen.
RESULTS
Biological activities of MAbs to VP70
The biological activities of the MAbs are listed in Table 1 
+ -14-07~ + + * Neutralization titre > 1:100 by 50°.~ plaque reduction without complement. t Inhibits fusion of previously infected cells at titre > 1 : 100. :~ Rabbit monospecific polyclonal antibody produced by immunization with purified fusion protein (Walsh et al., 1985) . previously infected cells. Each of these antibodies inhibited fusion at an antibody concentration of 6 to 10 gg/ml. Below this concentration syncytia began to form. The remaining six MAbs neutralized virus but did not inhibit fusion.
Binding oJ" MAbs to VP70 and competition binding
The binding characteristics of the monoclonal antibodies described a spectrum of curves ( Fig.  1 a, b, c) . Although the binding characteristics may be affected by the avidity of the alkaline phosphatase-labelled rabbit anti-mouse IgG antibody, no apparent relationship between avidity and isotype was noted. The fusion-inhibiting MAbs all demonstrated relatively high avidity (i.e. plateau A410) whereas the neutralizing MAbs bound with high and low avidity (Fig. 1) . Thus, although neutralization was not related to binding characteristics, the ability to inhibit fusion was correlated with relatively high avidity binding to VPT0. Both non-neutralizing MAbs bound to VPT0 with low avidity (Fig. 1 c) . To examine the topographical characteristics of VP70, the epitopes that subserve neutralization and fusion inhibition were defined by competitive binding. Four of the fusioninhibiting MAbs (L4, A4, A5, A6), three neutralizing MAbs (R661, R294, R392) and the two non-neutralizing MAbs (A8, A9) were labelled with alkaline phosphatase. Competition was arbitrarily defined as complete, partial or minimal if the unlabelled antibody prevented attachment of labelled antibody by >90~o, 50 to 75~o or <45~o respectively when the competitor was used at 10 ~tg/ml. Competition by two 17D yellow fever virus monoclonal antibodies served as a control. The competitor concentration was at least 100 times greater than the plateau concentration of the binding curves (Fig. 1) . Complete competition (> 90~) was required for classification as a distinct epitope. The competition criteria were partially based upon the values obtained, and are similar to criteria used by other investigators (Stone & Nowinski, 1980; Iorio & Bratt, 1983) . Although Stone & Nowinski suggest that partial competition between antibodies may result from differences in avidity, we did not find that this occurred. Both low (R294, R661) and high (R13-1, R392) avidity antibodies gave comparable competition with a labelled high avidity antibody (R392). The results of these experiments are summarized in Table 2 .
At least two and perhaps three fusion-inhibiting epitopes on VP70 were described by competitive binding. One epitope was described by L4, and a second fusion-inhibiting epitope by A4, A5 and A6. A third possible epitope was described by R235, as it failed to compete partially with labelled A4, A5 or A6 and only partially competed with labelled L4. R235, if used at high concentrations, may have given greater competition with labelled L4, as suggested by Fig. 2(a) . Unfortunately, R235 did not retain specific binding activity when labelled with alkaline phosphatase and thus we could not determine whether unidirectional competition occurred between these fusion-inhibiting MAbs and R235. Fig. 2 graphically illustrates competition curves between MAbs representing the defined epitopes. Fig. 2(a) illustrates that complete competition with labelled L4 occurs only with the homologous unlabelled antibody, while partial competition by R235 and A6 was noted. A4 and A5 also gave partial competition with labelled L4 (data not shown). This suggests partial overlap of these fusion-inhibiting epitopes. There was minimal competition between labelled L4 and the neutralizing and nonneutralizing MAbs. Fig. 2(e) illustrates complete competition between unIabelled A6 and labelled A4 and minimal competition by L4 and R235. A4, A5 and A6 all demonstrated complete cross-competition as outlined in Table 2 . The neutralizing (R392, R661) and nonneutralizing (A8) MAbs also showed minimal competition with labelled A4. A single epitope was described by the six non-fusion-inhibiting neutralizing MAbs (Table 2) . Partial competition occurred between labelled R661 and A6 (Fig. 2d ) and A4 and A5 (not shown) but minimally with R235 or L4, suggesting a possible spatial proximity of the neutralizing epitope with the fusion-inhibiting epitopes. The two non-neutralizing antibodies cross-competed but did not compete with other MAbs, and thus may describe a single non-neutralizing epitope (Fig. 2b) . In all, four and possibly five distinct epitopes on the fusion protein were described by the 13 MAbs in competitive binding studies.
In similar competition experiments, both polyclonal rabbit sera to VP70 demonstrated complete competition with the labelled neutralizing and fusion-inhibiting MAbs. Since one of these competing polyclonal sera (14-06) did not inhibit fusion, we examined its ability to block infected with RSV at an m.o.i, of 0.01 and incubated for 8 h. The medium was removed and overlaid with medium containing MAb alone, rabbit serum (14-06) alone or MAb plus rabbit serum. The MAb was used at the lowest concentration which inhibited fusion (6 to 10 gg/ml) and the polyclonal rabbit serum at a 1 : 100 dilution. After 3 days the cell sheet was examined for syncytium formation. As described previously, the rabbit serum alone did not inhibit fusion while the MAbs prevented syncytium formation. The cells incubated with the mixture of MAb and polyclonal serum did not develop syncytia. Thus, although the polyclonal serum competed with the MAbs in a solid-phase assay, it did not block their biological activity.
To investigate further the binding characteristics of the MAbs to VP70, Western blot analysis was performed using purified VP70 as the antigen. This demonstrated that all MAbs except the fusion-inhibiting antibody R235 reacted with the dimer of VP70 (Fig. 3a) while all MAbs including R235 reacted with the monomer of VP70 (Fig. 3b) . This finding is consistent with the competitive binding studies which suggest that R235 describes a fusion-inhibiting epitope distinct from the two epitopes described by L4 and A4, A5 and A6.
When VP70 was treated with heat and 2-ME prior to electrophoresis, L4, A8 and A9 reacted strongly with the 48K fragment (Fig. 3c) , but none of the other MAbs reacted with either fragment. A weak reactivity to the 23K fragment was noted with L4, suggesting some degree of cross-reactivity between these fragments.
DISCUSSION
Recent studies have identified the role of the RSV fusion protein in viral infectivity and spread, and animal experiments suggest that antibody to this protein may be important in immunity (Taylor et al., 1984; Walsh et al., 1984b) . In this report, we describe the topographical relationship of important epitopes on the fusion protein. Recently, MAbs have been used to evaluate clinical RSV isolates for possible strain variation (Anderson et al., 1985) . The clinical importance of any strain differences, however, is unclear. A better appreciation of significant strain variation might be obtained by using monoclonal antibodies to the biologically important epitopes of the fusion protein as defined in this report. A similar approach has been used to evaluate strain variation of Newcastle disease virus (Iorio et al., 1984) .
Four or five antibody-binding sites, or epitopes, on the RSV fusion protein are described based upon biological activity, solid-phase competitive binding and Western blotting assays using 13 MAbs. The partial competition between MAbs directed to these epitopes may reflect topographical proximity of the binding sites, although changes in the tertiary structure of the antigen induced by the binding of one antibody may alter the binding of a second antibody to a distinct epitope. Thus, the distance between epitopes or their actual spatial arrangement cannot be accurately determined from these studies. Binding of antibody to two or three of these epitopes inhibits the fusion function of VP70 and neutralizes virus while a separate epitope subserves neutralization only. Although not conclusive, the Western blot data do suggest that one of the fusion-inhibiting neutralizing MAbs, R235, binds to a site different from the other four, L4 and A4, A5, and A6. It is of interest that the fusion protein possesses distinct epitopes which subserve fusion and neutralization. Presumably, antibody that binds to one of the fusion epitopes neutralizes virus by preventing fusion of viral and cellular membranes, thus blocking viral penetration. Antibody binding to the neutralizing epitope probably neutralizes virus by a different mechanism, perhaps by steric hindrance of virus attachment, or by prevention of uncoating or transcription of the viral genome.
Although as many as three fusion-inhibiting epitopes were found, it is not known whether any of the antibodies actually bind to that sequence of the fusion protein which mediates fusion of cellular membranes. The active fusion site of the Sendai virus fusion protein and of the influenza haemagglutinin are unique short peptide regions (Atassi & Webster, 1983; Choppin & Scheid, 1980) . Recently, the amino acid sequence of the RSV fusion protein, and the presumed active fusion region, have been reported . Alternatively, antibody may sterically inhibit the active fusion site from its postulated interaction with cellular membranes (Hsu et al., 1981) .
The study of paramyxovirus infectivity prompted Merz et al. (1981) to suggest that a successful vaccine should induce antibody that inhibits the function of the fusion protein.
Although fusion-inhibiting antibody can be induced by immunization of animals with purified VP70, antibody which neutralizes virus but does not inhibit fusion may also result (Waish et al., 1985) . A more uniform and reliable immune response to vaccination is desirable, especially in light of the problems following vaccination with a formalin-inactivated RSV vaccine (Kim et al., 1969) . Newer strategies for the development of viral vaccines include the use of short peptide fragments synthesized from the known amino acid sequence of viral proteins (Arnon et al., 1983) . Immunization with a fragment of the RSV fusion protein which consistently induces fusion-inhibiting and neutralizing antibody is a reasonable approach to vaccine development. The binding sites that subserve fusion inhibition are candidates for such a synthetic vaccine. The ability of L4, a fusion-inhibiting neutralizing MAb, to bind to the 48K fragment of reduced, denatured VP70 suggests that this fusion-inhibiting epitope may be amenable to the synthetic peptide approach to vaccine development since the antigenic site remains reactive under denaturing conditions and may be a continuous epitope region. Analysis of enzymic or cyanogen bromide cleavage fragments of VP70 will be useful to localize this epitope more precisely.
A theoretical problem when peptide fragments are used for immunization is the presence of blocking antibodies which may prevent the peptide fragment-induced antibodies from binding to the native protein in vivo. Blocking of neutralization by a non-neutralizing monoclonal antibody that competed with a neutralizing MAb in a competitive binding assay has been described (Massey & Schochetman, 1981) . We did not observe blocking of the in vitro activity of any fusion-inhibiting MAb by a non-fusion-inhibiting polyclonal antiserum despite competition in the solid-phase competitive binding assay. The reasons for this apparent discrepancy can only be speculative, but similar observations with neutralization by MAbs have been reported (Schlesinger et al., 1984) .
